Clinical trials are designed with precision. They are executed in variability. Enrollment curves rarely follow projections. Screen failure rates shift. Sites activate at different…
In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% -…
Over the last decade, China has become a key destination for oncology clinical trials, with Chinese sites increasingly incorporated within…
The design of depot strategy has long been framed as a fundamental trade-off within the clinical trial supply chain. Sponsors…
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the…
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained…
